Andrew is a co-founder of KalVista Pharmaceuticals and its CEO. Prior to KalVista, Andrew held various senior management positions including chief executive, vice president of business development and director of clinical and regulatory affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licenses, IP and technology licenses, and R&D alliances.
Andrew received a BA from the University of Utah, and MBA from The Wharton School, University of Pennsylvania, with a major in Finance.
Ed is a co-founder of KalVista and joined as Chief Scientific Officer in 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center. He has more than 27 years of research experience in vascular biology and diabetic complications. His laboratory identified novel mechanisms of action for the plasma kallikrein system, which are implicated in diabetic macular edema, vascular injury, and angioedema. This NIH-funded research was published in Nature Medicine and other high impact journals.
Ed received his Ph.D. in Biochemistry from Boston University and completed postdoctoral training at the Joslin Diabetes Center and Harvard Medical School.
Andreas joined KalVista as Senior Vice President of Medical in March 2017. Dr. Maetzel was most recently Vice President, Global Medical Affairs at BioCryst Pharmaceuticals. Prior to that he was Vice President, Clinical Development & Regulatory Affairs at Cornerstone Therapeutics Inc. Previously, Dr. Maetzel held a clinical development role at BioCryst, and also positions in strategy consulting and health technology assessment strategy at Amgen.
He is Visiting Scientist at the University Hospital Zurich and Charité Hospital Berlin, and maintains an appointment as Adjunct Professor, Institute for Health Policy, Management & Evaluation, University of Toronto. Dr. Maetzel obtained both a Ph.D and M.Sc. in Clinical Epidemiology from the University of Toronto and a Dr. med. at the University of Hannover, Germany.
Ben joined KalVista as Chief Financial Officer in August 2016. Mr. Palleiko has twenty years of industry experience as a life sciences investment banker and senior executive of several public and private companies. Prior to joining KalVista, Mr. Palleiko was a Managing Director of H.C. Wainwright & Co. LLC and also co-founded an oncology drug development company, Cielo Therapeutics, Inc. He previously was Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co.
Earlier in his career Mr. Palleiko was a Director and Head of Life Sciences Investment Banking at SunTrust Robinson Humphrey and prior to that at Robertson Stephens. He has completed over 50 transactions of all types and raised in excess of $2 billion in capital. Mr. Palleiko holds a M.B.A. in Finance and a M.A. in International Relations from the University of Chicago, and a B.A. in Quantitative Economics from Tufts University. He served as a Naval Aviator in the U.S. Navy.
Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work he spent several years at Roussel-UCLAF and Hoechst Marion Roussel before joining Ferring Pharmaceuticals. Chris led the Biology group and was responsible for transition of candidates into development. In 2008, Chris co-led the spin-out of Vantia Ltd and most recently was Chief Operating Officer where he was responsible for development activities through Phase 3 trials.
In his position as Chief Development Officer, Chris is responsible for all development-related activities within KalVista Pharmaceuticals.